The next wave of CVRM innovation combines growing clinical development activity with a shift towards greater biological precision, more convenient and durable treatment, earlier and potentially disease-modifying intervention, and closer integration of therapeutics and diagnostics. CVRM trial starts increased from 759 in 2015 to 1,063 in 2025, while the clinical-stage pipeline comprises 815 Phase 1–3 assets across a broad range of diseases. Many assets are also being developed across multiple indications, reflecting shared biology and overlapping patient populations.

Backbone agents such as incretin-based therapies and SGLT2 inhibitors can improve multiple CVRM risk factors and reset the overall risk baseline, changing what constitutes residual unmet need for more targeted therapies. Established antihypertensive, lipid-lowering and heart-failure treatments are nevertheless expected to remain central to routine care. For innovators, the challenge is therefore to understand this upstream-downstream interplay, define the patients most likely to benefit from additional treatment and explore combination approaches, with implications for the overall CVRM portfolio strategy.

Pharma should assess CVRM opportunities at disease and market-segment level rather than relying on the aggregate growth outlook alone. Excluding obesity, the CVRM market is forecast to grow at 9% annually from 2026 to 2030 and reach $418 billion, but growth trajectories vary substantially according to epidemiology, unmet need and therapeutic maturity. MASH and dyslipidaemia illustrate how innovation can create attractive growth pockets, while less dynamic, stagnant or declining segments within the same broad market can mask those opportunities.

Biomarker lowering needs to translate into meaningful clinical benefit beyond the current standard of care if a new residual-risk therapy is to change practice. Recent results illustrate that this translation cannot be assumed. Ziltivekimab lowered free IL-6 and hsCRP in ZEUS but did not reduce MACE, while pelacarsen lowered Lp(a) in Lp(a)HORIZON but did not meet its primary cardiovascular endpoint. Detailed pelacarsen results were not yet available at the time of writing, limiting strong conclusions, while ongoing outcomes trials will test other agents and populations.

Successful CVRM commercialisation requires innovators to address evidence, access and implementation alongside the therapy itself. The article identifies five priorities: extensive early market shaping; evidence leadership focused on patient- and health-system-relevant outcomes; reassuring payers through clear value, identifiable target populations and responsible pricing; preparing care pathways and diagnostic infrastructure for adoption; and ongoing